Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TAFASITAMAB-CXIX for Marginal zone lymphoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 13 adverse event reports in the FDA FAERS database where TAFASITAMAB-CXIX was used for Marginal zone lymphoma.

Most Reported Side Effects for TAFASITAMAB-CXIX

Side Effect Reports % Deaths Hosp.
Disease progression 218 29.6% 41 8
Lymphoma 158 21.5% 3 7
Off label use 126 17.1% 7 20
Death 53 7.2% 53 3
Drug ineffective 39 5.3% 19 5
Blood lactate dehydrogenase increased 34 4.6% 14 0
Diffuse large b-cell lymphoma 32 4.4% 13 4
Malignant neoplasm progression 30 4.1% 5 3
Neutropenia 30 4.1% 5 7
Polyneuropathy 29 3.9% 0 8
Covid-19 28 3.8% 9 17
Cytopenia 25 3.4% 0 1
Ill-defined disorder 21 2.9% 0 1
Product use issue 21 2.9% 2 1
Neoplasm progression 20 2.7% 7 0

Other Indications for TAFASITAMAB-CXIX

Diffuse large b-cell lymphoma (429) Product used for unknown indication (115) Follicular lymphoma (58) Diffuse large b-cell lymphoma refractory (31) Lymphoma transformation (23) Lymphoma (13) Diffuse large b-cell lymphoma recurrent (8) Non-hodgkin's lymphoma (7) B-cell lymphoma (5) Marginal zone lymphoma refractory (5)

Other Drugs Used for Marginal zone lymphoma

RITUXIMAB (706) IBRUTINIB (519) LENALIDOMIDE (321) OBINUTUZUMAB (188) ETOPOSIDE (176) BENDAMUSTINE (174) CYCLOPHOSPHAMIDE (173) IFOSFAMIDE (151) METHOTREXATE (138) DOXYCYCLINE (135)

Related Pages

TAFASITAMAB-CXIX Full Profile All Marginal zone lymphoma Drugs TAFASITAMAB-CXIX Demographics TAFASITAMAB-CXIX Timeline